Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by mercedesmanon Mar 22, 2022 10:51am
177 Views
Post# 34534343

RE:A Cynic Might Say

RE:A Cynic Might Say
Domino55 wrote: - That "forces" are setting up to make the recent option handout look like a bargain at 32 cents.

A cynic might also say that these "forces" seem to have no limit on what they are prepared to do to make this late stage, multi P3 look as un-buyable as possible.



An optimist might say that as well ;)

The more "unbuyable, the more owners retain for themselves"  As in..."this pie is crrap, you should avoid it altogether, it tastes really bad...I'll just suffer through eating myself, cuz I just hate to throw things out"

All as we progress inexorably* toward interim Trial results, and Trial completion (PMX), and 35 person Trial start (DIMI - 6 weeks in Clinic and 6 weeks at home).

This is the ONLY thing that matters in the case of P3 Companies (eventual Trial completion and FDA Ruliing).  Paradigm assumes PMX has a 75% probability of approval.  Mgt.s is telling us that the Tigris Trial is "exceeding expectations". They only have to "confirm" Euphrates subset results. FDA Trial parameters are highly favourable (2:1, open label, Bayesisan, use of Euphrates data, etc.)  Seto says DIMI approval is a "when, not if" outcome.

*inexorably

adverb
  1. in a way that is impossible to stop or prevent.

<< Previous
Bullboard Posts
Next >>